Palisade Bio (PALI) announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board, CAB. Palisade plans to submit an Investigational New Drug application for a Phase 2 study of PALI-2108 in UC in the first half of 2026, with parallel development planning underway in FSCD.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI: